Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?

Clin Neurol Neurosurg. 2021 Sep;208:106887. doi: 10.1016/j.clineuro.2021.106887. Epub 2021 Aug 13.


We report a case of Guillain-Barré syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have been increasingly reported. After reviewing the available literature, considering the annual incidence of GBS, in this historical moment, the public health systems cannot afford an unjustified distrust in vaccines, caused by misinterpretation of epidemiological data. Nonetheless, it is important for clinicians to promptly recognize neurological complications potentially associated with COVID-19 vaccinations and report them to pharmacovigilance agencies.

Keywords: AstraZeneca; COVID-19; Guillain-Barré syndrome; Vaccine.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / adverse effects*
  • ChAdOx1 nCoV-19
  • Guillain-Barre Syndrome / etiology*
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2


  • COVID-19 Vaccines
  • ChAdOx1 nCoV-19